Effect of faecal occult blood screening on mortality from colorectal cancer: results from a randomised controlled trial

被引:219
作者
Scholefield, JH [1 ]
Moss, S
Sufi, F
Mangham, CM
Hardcastle, JD
机构
[1] Univ Nottingham Hosp, Div GI Surg, Nottingham NG7 2UH, England
[2] Canc Screening Evaluat Unit, Sutton SM2 5NG, Surrey, England
关键词
D O I
10.1136/gut.50.6.840
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Three large randomised trials have shown that screening for colorectal cancer using faecal occult blood (FOB) tests can reduce the mortality from this disease. Two national pilot studies have recently been launched in the UK to investigate the feasibility of population screening for colorectal cancer in the National Health Service. The largest of the randomised trials was conducted in Nottingham and randomised 152 850 individuals between the ages of 45 and 74 years to receive biennial Haemoccult (FOB) test kit (intervention group) or to a control group. Aims: We have compared the mortality in the intervention group compared with the control group. Methods: The 152 850 randomised individuals were followed up through local health records and central flogging (Office for National Statistics) over a median follow up period of 11 years. Results: At a median follow up of 11 years there was a 13% reduction in colorectal cancer mortality (95% confidence interval 3-22%) in the intervention group despite an uptake at first invitation of only approximately 50%. The mortality reduction for those accepting screening was 27%. The reduction in mortality was independent of sex and site of tumour. There was no significant difference in mortality from causes other than colorectal cancer between the intervention and control groups. Conclusions: Although the reduction in colorectal cancer mortality was sustained, further follow up of this population is required to determine whether a significant reduction in the incidence of colorectal cancer will be achieved.
引用
收藏
页码:840 / 844
页数:5
相关论文
共 20 条
[1]   Fecal occult blood testing for colorectal cancer - Can we afford to do this? [J].
Ahlquist, DA .
GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 1997, 26 (01) :41-&
[2]   Screening for colorectal cancer: the heart of the matter [J].
Atkin, WS .
GUT, 1999, 45 (04) :480-481
[3]   Uptake, yield of neoplasia, and adverse effects of flexible sigmoidoscopy screening [J].
Atkin, WS ;
Hart, A ;
Edwards, R ;
McIntyre, P ;
Aubrey, R ;
Wardle, J ;
Sutton, S ;
Cuzick, J ;
Northover, JMA .
GUT, 1998, 42 (04) :560-565
[4]  
Breslow NE, 1980, STAT METHODS CANC RE, V1, DOI DOI 10.1097/00002030-199912240-00009
[5]  
Cuzick J, 1997, STAT MED, V16, P1017, DOI 10.1002/(SICI)1097-0258(19970515)16:9<1017::AID-SIM508>3.0.CO
[6]  
2-V
[7]   Randomised controlled trial of faecal-occult-blood screening for colorectal cancer [J].
Hardcastle, JD ;
Chamberlain, JO ;
Robinson, MHE ;
Moss, SM ;
Amar, SS ;
Balfour, TW ;
James, PD ;
Mangham, CM .
LANCET, 1996, 348 (9040) :1472-1477
[8]  
HARDCASTLE JD, 1989, LANCET, V1, P1160
[9]   Randomised study of screening for colorectal cancer with faecal-occult-blood test [J].
Kronborg, O ;
Fenger, C ;
Olsen, J ;
Jorgensen, OD ;
Sondergaard, O .
LANCET, 1996, 348 (9040) :1467-1471
[10]  
Lazovich D, 1995, J Med Screen, V2, P84